REMARKS

The Advisory Action dated March 12, 2010, indicated that the claim amendments presented in Applicant's prior after final Response and Amendment dated March 1, 2010, were not entered. Accordingly, claims 1, 12, 13, 18, 19, 21, 23-25, 29-31, 33-36, and 38-49 are currently pending in this application. Claims 12, 13, 18, 19, 29-31, and 41-49 stand withdrawn. Claims 12, 13, 18, 19, 21, 23, 24, 29-31, 33-36, and 38-49 are cancelled without prejudice or disclaimer as to the subject matter thereof. Claims 2-11, 14-17, 20, 22, 26-28, 32, 37, and 50 were previously cancelled without prejudice or disclaimer as to the subject matter thereof. Applicants respectfully reserve the right to prosecute the subject matter of the cancelled claims in one or more Continuation or Divisional applications. Claims 1 and 25 will be pending on entry of the current amendments.

Allowable Claims

Applicants appreciate the Examiner's indication that claims 1 and 25 are allowable. See Office Action Summary, item 5.

Rejections

35 U.S.C. § 112, 1st Paragraph, Written Description

Claims 38-40 were rejected under 35 U.S.C. § 112, 1st paragraph as allegedly failing to comply with the written description requirement. This rejection has been rendered moot by the cancellation of claims 38-40.

35 U.S.C. § 112, 1st Paragraph, Enablement

A. Claims 33-35

Claims 33-35 were rejected under 35 U.S.C. § 112, 1st paragraph as allegedly failing to

Patent Application No. 10/715,417 E.P.T. Straten et al. March 29, 2010

Attorney Docket No. 60820.000004

provide enablement. This rejection has been rendered moot by the cancellation of claims 33-35. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.

B. Claim 24

Claim 24 was rejected under 35 U.S.C. § 112, 1st paragraph as allegedly failing to provide enablement. This rejection has been rendered moot by the cancellation of claim 24. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.

35 U.S.C. § 112, 2nd Paragraph

A. Claims 23 and 34

Claims 23 and 34 were rejected under 35 U.S.C. § 112, 2nd paragraph as allegedly indefinite in the recitation of "... wherein the cancer disease is selected from the group consisting of" This rejection has been rendered moot by the cancellation of claims 23 and 34. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.

B. Claim 24

Claim 24 was rejected under 35 U.S.C. § 112, 2nd paragraph as allegedly indefinite in the recitation of the cell lines "MCF-7" and "FM3". This rejection has been rendered moot by the cancellation of claim 24. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.

4

Prior Art Rejections

A. 35 U.S.C. § 102 (b)

- 1.) Claims 21, 23, 36, and 40 were rejected under 35 U.S.C. § 102 (b), as allegedly anticipated by the disclosure of Andersen *et al* (Cancer Res., 2/2001, 61:869-872) as evidenced by Andersen *et al* (Cancer Res., 2001, 61:5964-5968). This rejection has been rendered moot by the cancellation of claims 21, 23, 36, and 40. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.
- 2.) Claims 21, 23, 36, and 40 were rejected under 35 U.S.C. § 102 (b), as allegedly anticipated by the disclosure of Andersen et al (Cancer Res., 2001, 61:5964-5968). This rejection has been rendered moot by the cancellation of claims 21, 23, 36, and 40. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.
- 3.) Claims 21, 23, 34-36, and 40 were rejected under 35 U.S.C. § 102 (b), as allegedly anticipated by the disclosure of International Publication No. WO 02/072631 (9/19/2002). This rejection has been rendered moot by the cancellation of claims 21, 23, 34-36, and 40. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.

B. 35 U.S.C. § 103(a)

- 1.) Claims 21, 23, 34-36, and 40 were rejected under 35 U.S.C. § 103(a) as allegedly obvious over Anderson et al (2001, 61:5964-5968) in view of U.S. Patent No. 6,572,864. This rejection has been rendered moot by the cancellation of claims 21, 23, 34-36, and 40. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.
- 2.) Claims 21, 23, 34-36, and 40 were rejected under 35 U.S.C. § 103(a) as allegedly obvious over Anderson et al (2/2001, 61:869-872) in view of U.S. Patent No. 6,572,864. This rejection has been rendered moot by the cancellation of claims 21, 23, 34-36, and 40. Applicants respectfully reserve the right to address this rejection in a Continuation or Divisional application.

Patent Application No. 10/715,417 E.P.T. Straten et al. March 29, 2010 Attorney Docket No. 60820,000004

CONCLUSION

An indication of allowance of all claims is respectfully solicited. Early notification of a favorable consideration is respectfully requested.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Date: March 29, 2010

By: Pobin

Robin L./Teskin Reg. No. 35,030

Hunton & Williams LLP 1900 K Street, N.W. Suite 1200 Washington, D.C. 20006-1109 (202) 955-1500 (Telephone) (202) 778-2201 (Facsimile) Robert C. Lampe, III Reg. No. 51,914